Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.